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Third, another limitation of this study is the relatively
small number of cases in both groups, thus requiring larger
differences in clinical outcomes to detect statistically signif-
icant differences (type II error).
Fourth, although strict criteria were used in the selection
of both the older and younger recipients, the final approval
for lung transplantation was dependant on the decision of
the multidisciplinary lung transplant selection committee.
There might be inherent bias against selection of older
patients based on overall clinical fitness and extent of
comorbidities.
Fifth, another limitation of this study is the short follow-up
time. Longer follow-up analyses are needed to assess the
safety and clinical outcome of lung transplantation in older
recipients.
Finally, this study only compares the survival of older and
younger lung transplant recipients. Lung transplantation
might not only affect survival but also the quality of life.
We have no objective information on the quality of life after
lung transplantation in the older or younger recipients as part
of this study. The real effect of lung transplantation can only
be assessed when survival and quality-of-life data are ana-
lyzed together.
In summary, lung transplantation can be performed safely
andwith comparable short-term andmedium-term survival in
selected patients older than 65 years.
Posttransplantation-related infections represent the major
cause of early mortality that might require adjustments in
immunosuppression protocols. Multidisciplinary consensus
is needed to determine the ethical standards in offering
lung transplantation to the elderly given the critically short
supply of donor organs.
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Discussion
Dr John C.Wain (Boston, Mass). I appreciate the chance to discuss
the article. Certainly I think the results are quite good, and Drs Bas-
tani and Ardehali and their colleagues are to be congratulated on
having not only completed this study but also their superlative re-
sults in terms of operative and perioperative morbidity and mortality
looking in a retrospective fashion at patients older than 65 years of
age. I think it is important to recognize that age greater than 65 years
is actually a pretty narrow window; it is just 65 to 72 years of age as
the maximum. Therefore we still have a question out there about
even older patients. That being said, though, the results still stand
for themselves in terms of the operative and perioperative morbidity
and mortality.
Before I get to specific questions, I would like to say that the
study also seems to validate 2 other things that are emerging con-
cepts, if you will, at least about lung transplantation in the United
States. The first is that the LAS system works. As I think you found
in your manuscript, the time waiting at a busy transplantation center
was reduced from 107 days to 47 days. Therefore the LAS is clearly
an improvement.
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The second is that ischemic times do not matter so much in the
modern era of lung transplantation, and I think that that is an inter-
esting observation, certainly one that seems to be growing and that
probably relates to standardized procurement and preservation and
the techniques of implantation.
But to return to the main thrust of the article, there were 3 con-
clusions I think they tried to stress. One is that lung transplantation
in older patients is safe, the second is that older patients die most
commonly from infectious causes, and the third is that nonstandard
lungs can be used safely for older patients. About the first point, with
which I would tend to agree, that the right selection of recipients al-
lows you to have a successful transplantation, I am curious because
in fact this is a comparison of single-lung transplantations in older
patients versus double-lung transplantations in younger patients,
and therefore we get into how you decide someone received a sin-
gle-lung transplant versus a double-lung transplant for the same dis-
ease because your groups were matched based on their initial
diagnosis. Therefore my question is as follows: in terms of selecting
the older patient for a transplantation procedure, which by default in
your case would be a single-lung transplantation procedure, are
there other things, other specifics, such as right ventricular end-dia-
stolic pressure, ejection fraction, or body mass index, that allow you
to more accurately identify the older patient that you would see as
a potential candidate for transplantation?
Dr Bastani. With regard to your question about more precisely
defining our patient population of 65 years and older, we did not
have enough older patients in the double-lung transplant group to
be able to make an adequate comparison. We did, however, have
a list of relative contraindications for the patients 65 years and older,
some of which were body mass index of less than 18 and greater
than 30, debilitation, and acute renal failure defined by creatinine
clearance. In general, our lung transplantation committee made an
effort not to list patients who had 2 or more of these relative contra-
indications.
Dr Wain. Were those the only relative contraindications? Was
there anything else, such as osteoporosis or bad social history or
any of those other things, that were in the mix?
Dr Bastani. By listing debilitation as one of the relative contra-
indications, we have the ability to introduce some subjectivity, and
yes, osteoarthritis and other characteristics could preclude patients
from receiving a lung transplant.
Dr Wain. The other question I have is this: How do you decide
that a 63-year-old patient with IPF, for example, received a double-
lung transplant and a 65-year-old patient with IPF receives a single-
lung transplant? Is there anything else other than their absolute age
that goes into your decision-making process that lets you decide that
the patient should receive a single- or a double-lung transplant in the
same relative age range?
Dr Bastani. At this time, despite our focus on a population of
patients 65 years and older, there is no absolute contraindication
on upper age limit with respect to single- versus double-lung trans-
plantation. If our lung transplantation committee deems a patient to
be clinically fit, despite advanced age of 65 years and older, he or she
might be a potential candidate for lung transplantation, including
double-lung transplantation.
Dr Wain. With regard to the second point about older patients
dying more of infection, I guess in looking at it I would say that
your data really say that your older patients just die more in that first
year. I say that because it looked like 6 of 8, or 75%, of the older
group of patients died of infectious causes in the first year, and al-
though the number of younger patients dying was much smaller, 2
of 3 died of those infectious causes. Therefore the first question is
as follows: Was there any specific type of infectious cause that the
patients in either group died of, and then, as an aside to that, was
there a difference between the infectious causes in the 2 groups?
Dr Bastani. Five of the 6 patients in the older group died of in-
fection of bacterial cause, and the other patient died of infection of
fungal cause. There were no patients in this group who died of infec-
tious cause secondary to a viral source. In the younger group both of
the patients died of infection of bacterial cause.
DrWain. Therefore you had bacterial infections in both groups.
Dr Bastani. Yes.
DrWain. Then along those lines, akin to the single- versus dou-
ble-lung transplantation, you have 2 different immunosuppressive
protocols. Was there any suggestion or thought that the difference
in induction immunosuppression might somehow relate to the likeli-
hood of infection or death in the first year? Do you have any other
experience to draw on using the interleukin 2 receptor blocker that
would suggest that is not as good, for instance, as the rabbit ATG
or vice versa?
Dr Bastani. We did not specifically look at that and compare
those 2 groups, although we did initially have a bias for selecting in-
terleukin 2 receptor antibody induction therapy for older patients
and vice versa for the younger patients, but we did not specifically
look at that.
Dr Wain. And why did you come to that bias, or what was the
rationale behind that?
Dr Bastani. Because older patients are more susceptible to im-
munosenescence, our group selects for interleukin 2 receptor anti-
body induction therapy for the older group because of its more
specific and less broadly immunosuppressive action.
DrWain.That is perfectly fine. To the last point in the study, that
nonstandard lungs are okay or safe in older patients, I guess I would
say that might be a little bit overstated. I say that because, having
looked at that table of your donor characteristics, although there
was clearly a preponderance of lungs from older donors in your
older age group, functionally the lungs seemed much the same in
terms of their overall PO2, and in fact, there was a little trend for a pre-
ponderance of donors who had a significant smoking history in the
younger group compared with the older group. Recognizing that
elastic fibers deteriorate as you get older and that sort of thing, if I
needed a lung transplantation, I personally would want a lung
from a 60-year-old marathon runner instead of a 48-year-old indi-
vidual who smoked a lot. I just wondered if there are any other pa-
rameters, smoking, for instance, that you look at more critically
than, say, age, which is a crude marker at best, in terms of trying
to select donor lungs for older patients or patients who you might
consider at higher risk.
Dr Bastani.We were surprised by our findings that a larger pro-
portion of the patients in the younger group received lungs from
smokers. We did look at other parameters. One of the parameters
was donor age greater than 55 years. There were also other param-
eters that we examined. Other studies demonstrate smoking history
to be a significant predictor as well. I am not certain whether this
finding will be predictive of a negative outcome in our younger pa-
tients, but we did examine other nonstandard donor lung parameters.
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I should note that a larger number of the patients in the older group
had multiple criteria that met the nonstandard donor lung parameters
compared with the younger patients, who had a single-criterion pa-
rameter.
Dr Wain. I have 1 final question about selecting donor lungs. Is
there anything that you can think of or anything that you routinely
do that is a little more precise than just donor age or smoking history
or, you know, what the chest radiograph looks like? Do you do any
routine chest computed tomographic scanning or routine bronchoal-
veolar lavage or something like that that would give us a better sense
of the kind of true anatomic and inflammatory state of the donor lung
than just what the PO2 is at some little snapshot in time or the donor’s
age?
Dr Bastani. At our institution, we routinely perform bronchos-
copies on all donor lungs, and if, for example, there is any question
of whether there is an infiltrate on chest radiography or there are any
significant findings on bronchoscopy, we do perform chest com-
puted tomographic scanning on those patients; however, we do
not routinely perform chest computed tomographic scanning on
all donors.
Dr Wain. Again, congratulations, and thanks very much for
letting me see the manuscript ahead of time.
Dr Yoshiya Toyoda (Pittsburgh, Pa). Congratulations on your
excellent presentation and outcome.
I would like to make a comment. Over the last year and a few
months, I have done 66 lung transplantations, and of these, 18 pa-
tients, about 25%, were age 65 years and older, including an 81-
year-old man for whom I did a left single-lung transplantation for
his IPF and moderate pulmonary hypertension. Fortunately, 30-
day survival has been 100%, but I lost 2 patients, one from Pseudo-
monas-induced pneumonia and the other from sepsis. Therefore I
agree with your conclusion. Probably these older patients should
be managed with less immunosuppression.
Dr Bastani. Thank you.
Dr Walter Klepetko (Vienna, Austria). I enjoyed your article
very much, and I want to congratulate you on these very good out-
come data.
One thing was surprising to me and struck me a bit. You showed
us an approximate freedom from BOS of only 50% after 1 or 11ˇ/2
years. This is somewhat low compared with data that we recently
have heard in which several multicenter studies have shown free-
dom from BOS after 3 years in the range of 75% to 80%. Do you
think that at least in the cohort of your older patients that this is
the price you are paying now when you are using lungs that are
not so ideal on the one hand and on the other hand potentially
have altered your immunosuppressive regimen in a way that BOS
might likely occur more frequently?
Dr Bastani.We were surprised by the pattern in which patients
demonstrated the incidence of BOS, particularly the older patients,
in whom there was a steady decrease in the incidence of BOS-free
survival, and then that leveled off. BOS was one of the secondary
end points that we examined. One explanation for differences in
our data compared with those of the multicenter study you just
eluded to might be in our definition of BOS; we defined BOS as
a 20% or greater decrease in forced expiratory volume in 1 second.
We did not routinely treat all patients with BOS or perform biopsies
on all patients with BOS.
DrKlepetko. I have one question regarding your acceptance cri-
teria. You had obstructive cardiovascular disease as an exclusion
criteria. How did you handle patients in whom the obstructive dis-
ease was already fixed, let us say, having a history of a bypass
operation 2 years before or a stent application with no further
obstructions there at the time of their evaluation?
Dr Bastani. Patients with prior history of percutaneous translu-
minal coronary angioplasty or bypass operation to correct obstruc-
tive coronary artery disease who were deemed to be free of
coronary artery disease, as assessed by means of left heart catheter-
ization, at the time of presentation to the lung transplantation com-
mittee were not excluded from consideration for lung
transplantation.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). I really en-
joyed your presentation.
We actually have an article that was just published this week (Am
J Transplant. 2007;7:1271-7) in which we compared outcomes of
lung transplantation in older and younger patients, and even with
age-adjusted mortality, we did find a higher risk of death over
time after lung transplantation in patients older than 60 years versus
those younger than 50 years. When you compare at a specific age
cutoff, such as older than 65 versus less than 65 years, there is not
much of a difference between a 64-year-old and a 66-year-old.
Did you look at your data with a wider age spread to see whether
you have an age difference?
Dr Bastani. We did not examine our subset of populations,
for example, 60 to 64 years, to determine whether survival was
similar to that seen in those older than 65 years or maybe those youn-
ger than 60 years, but certainly that is something that I think we need
to go back and look at to see whether we need to redefine our
parameters.
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